[Blood levels of medium molecular weight peptides and lipid peroxidation activity in the differential diagnosis of diffuse toxic goiter]. / Uroven' srednemolekuliarnykh peptidov v krovi i aktivnost' perekisnogo okisleniia lipidov v differentsial'noi diagnostike diffuznogo toksicheskogo zoba.

A study was made of the level of medium molecular peptides (MMP) and lipid peroxidation (LRO) activity in 36 patients with Basedow's disease of various degrees of severity and in patients with functional diseases of the nervous system. A statistically significant rise of the blood level of MMP in patients with Basedow's disease was established with relation to a group of healthy persons and patients with functional diseases of the nervous system. Correlations were found between the blood level of MMP, LPO activity and absorption of radioactive iodine by the thyroid. The blood level of MMP should be used as a screening test for clinico-laboratory diagnosis to differentiate between Basedow's disease and functional diseases of the nervous system.

[The effect of combined therapy with the use of thymalin and piracetam on the level of middle-molecule peptides in the blood and on the lipid peroxidation activity in patients with diffuse toxic goiter]. / Vliianie kompleksnoi terapii s primeneniem timalina i piratsetama na uroven' srednemolekuliarnykh peptidov v krovi i aktivnost' perekisnogo okisleniia lipidov u bol'nykh s diffuznym toksicheskim zobom.

The content of medium-weight molecular peptides (MMP), lipid peroxidation (LPO) activity, the profile of blood thyroid hormones, and radioactive iodine absorption by the thyroid were determined in 104 patients with light, moderate and grave diffuse toxic goiter (DTG). The content of MMP in the blood correlated with the gravity of DTG and thus may serve an additional test for its determination. Depending on the treatment 66 patients with DTG of medium gravity were distributed into 5 groups: group I included patients given mercazolyl, group II patients on lithium carbonate, group III patients who received mercazolyl and thymalin, group IV patients on mercazolyl and piracetam, and group V included patients given mercazolyl, thymalin and piracetam. A study was made of the blood content of MMP and LPO activity before therapy and after euthyroidism attainment. The treatment with the use of mercazolyl, thymalin and piracetam was found to produce a beneficial effect on the parameters under study and the clinical course of DTG.